tiprankstipranks
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H (GZPHF)
OTHER OTC:GZPHF

Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF) Price & Analysis

4 Followers

GZPHF Stock Chart & Stats

$2.34
$0.00(0.00%)
At close: 4:00 PM EST
$2.34
$0.00(0.00%)

Bulls Say, Bears Say

Bulls Say
Revenue GrowthTTM revenue up roughly 77% shows durable top-line momentum across products and channels. Sustained revenue expansion boosts scale economics, increases bargaining power with suppliers and payors, and creates optionality to fund R&D, marketing or margin-restoration efforts over months.
Diversified Business ModelA multi-segment model (proprietary TCM, chemical/Western drugs, and distribution/retail) provides multiple revenue engines and vertical integration benefits. Distribution scale and product mix reduce dependence on single tenders or products, improving resilience and cross-sell potential over the medium term.
Moderate Leverage And Equity BaseDebt-to-equity near 0.55 with growing equity indicates a moderate capital structure that preserves capacity to fund working capital or targeted investments. Compared with highly levered peers, this provides financial flexibility to execute strategy, though the rising trend requires monitoring.
Bears Say
Weak Cash GenerationA switch to negative FCF in 2025 and only modestly positive FCF TTM signals deteriorating cash conversion. That reduces the company's ability to self-fund capex, R&D and dividends, heightens reliance on external financing, and raises earnings-quality concerns over the coming months.
Margin CompressionSignificant margin erosion despite revenue growth points to adverse mix, pricing pressure or rising costs. Sustained lower gross and operating margins limit cash flow generation, reduce reinvestment capacity and compress profitability even if revenues remain elevated over the medium term.
Rising Leverage And Lower ROEDebt rising while ROE declines signals weakening capital efficiency and higher balance-sheet risk. Lower returns on equity reduce internal funding and may raise the cost of new capital, constraining strategic initiatives and increasing vulnerability to economic or sector shocks over the next several months.

Guangzhou Baiyunshan Pharmaceutical Holdings Company News

GZPHF FAQ

What was Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price range in the past 12 months?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H lowest stock price was $1.99 and its highest was $2.64 in the past 12 months.
    What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap?
    Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap is $4.76B.
      When is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date?
      Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date is Aug 14, 2026 which is in 50 days.
        How were Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s earnings last quarter?
        Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H released its earnings results on Apr 27, 2026. The company reported $0.161 earnings per share for the quarter, beating the consensus estimate of N/A by $0.161.
          Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H overvalued?
          According to Wall Street analysts Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pay dividends?
            Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pays a Quarterly dividend of $0.066 which represents an annual dividend yield of 7.89%. See more information on Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H dividends here
              What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate?
              Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H have?
              Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H has 219,900,000 shares outstanding.
                What happened to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price movement after its last earnings report?
                Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H reported an EPS of $0.161 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H?
                  Currently, no hedge funds are holding shares in GZPHF
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Smart Score

                    6
                    Neutral
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10

                    Company Description

                    Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H

                    Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials and their intermediates, alongside natural and biological remedies, serving both the Chinese domestic market and international clientele. The company's operations are strategically divided into four primary segments: Great Southern TCM, Great Commerce, Great Health, and Others. Beyond its manufacturing activities, GBPHCL is actively involved in the import, export, wholesale, and retail of both Western and Chinese medicines, as well as medical equipment. The company also develops, manufactures, and sells various consumer goods including beverages, food products, health supplements, pre-packaged foods, dairy items, and diverse pharmaceutical forms such as tablets, capsules, lozenges, and injections, in addition to traditional items like tortoise herb jelly. Furthermore, GBPHCL makes strategic investments in the broader health industry, covering areas like medical services, health management, wellness initiatives, and elderly care. It also provides commercial and advertising solutions. As of December 31, 2021, the company maintained a substantial retail presence, managing 154 chain pharmacies operating under brands like Cai Zhi Lin, Jian Min, GPC Prescription Pharmacy, and Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd, supplemented by an additional 22 independent retail stores. Established in 1997, the company originally operated as Guangzhou Pharmaceutical Company Limited before adopting its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. Its headquarters are situated in Guangzhou, China.

                    Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF) Earnings & Revenues

                    GZPHF Stock 12 Month Forecast

                    Average Price Target

                    $2.93
                    ▲(25.37% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","2":"$2","3":"$3","1.5":"$1.5","2.5":"$2.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.933604,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.933604,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.933604,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.93</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,1.5,2,2.5,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.274,2.3247387692307693,2.3754775384615385,2.426216307692308,2.476955076923077,2.5276938461538463,2.5784326153846155,2.6291713846153844,2.6799101538461536,2.730648923076923,2.781387692307692,2.8321264615384614,2.8828652307692306,{"y":2.933604,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.274,2.3247387692307693,2.3754775384615385,2.426216307692308,2.476955076923077,2.5276938461538463,2.5784326153846155,2.6291713846153844,2.6799101538461536,2.730648923076923,2.781387692307692,2.8321264615384614,2.8828652307692306,{"y":2.933604,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.274,2.3247387692307693,2.3754775384615385,2.426216307692308,2.476955076923077,2.5276938461538463,2.5784326153846155,2.6291713846153844,2.6799101538461536,2.730648923076923,2.781387692307692,2.8321264615384614,2.8828652307692306,{"y":2.933604,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.034,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.115,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.224,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.293,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.274,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.274,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.274,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.201,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.274,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.274,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.274,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.274,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.274,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    China Medical System Holdings
                    Livzon Pharmaceutical Group
                    Shanghai Fosun Pharmaceutical (Group) Co
                    China Resources Pharmaceutical Group Ltd.
                    Grand Pharmaceutical Group Limited

                    Ownership Overview

                    4.48%91.72%
                    Insiders
                    ― Other Institutional Investors
                    91.72% Public Companies and
                    Individual Investors

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks